Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report)'s stock price dropped 5.3% during trading on Friday . The stock traded as low as $0.62 and last traded at $0.62. Approximately 693,742 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 1,308,265 shares. The stock had previously closed at $0.65.
Elite Pharmaceuticals Stock Performance
The company has a quick ratio of 5.44, a current ratio of 7.23 and a debt-to-equity ratio of 0.09. The company has a 50 day moving average of $0.59 and a 200 day moving average of $0.54. The firm has a market cap of $675.90 million, a price-to-earnings ratio of -62.97 and a beta of 0.25.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter. Elite Pharmaceuticals had a negative return on equity of 9.88% and a negative net margin of 10.26%.The business had revenue of $40.21 million during the quarter.
About Elite Pharmaceuticals
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
